Home|Journals Follow on Twitter| Subscribe to List

Directory for Medical Articles
 

Open Access

Review Article



HDL-C as a new therapeutic target in the treatment of dyslipidemia

Sahin I.

Cited by (2)

Abstract
Clinical and epidemiological studies have suggested that low plasma levels of high-density lipoproteins cholesterol (HDL-C) are independently associated with an increased risk of cardio-vascular diseases (CVD). Accumulated data from epidemiologic, animal models and clinical studies support the view that raising HDL may be an effective new target to decrease cardio-vascular risks. New insights in the understanding of the physiology, mechanisms and pathways by which HDL may reduce atherosclerosis allow new promising agents for increasing plasma HDL-C. In this regards, apo-AI analogs, acute HDL-C infusions therapies and new cholesteryl ester transfer protein CETP inhibitors have opened new expectations in the treatment of CVD.

Key words: HDL, cardiovascular risks, treatment



Share this Article


Advertisement
Journal of Complementary Medicine Research

SUBMIT YOUR ARTICLE NOW


ScopeMed.com
BiblioMed Home
Follow ScopeMed on Twitter
Author Tools
eJPort Journal Hosting
About BiblioMed
License Information
Terms & Conditions
Privacy Policy
Contact Us

The articles in Bibliomed are open access articles licensed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License (https://creativecommons.org/licenses/by-nc-sa/4.0/) which permits unrestricted, non-commercial use, distribution and reproduction in any medium, provided the work is properly cited.
ScopeMed is a Database Service for Scientific Publications. Copyright © ScopeMed® Information Services.